Researchers in Oxford have found that an individual’s immune system – and in particular the presence of T-cells amongst tumour cells - may play an important role in survival after surgery to remove pancreatic cancer.
The study by the University of Oxford’s Department of Oncology and Kennedy Institute, supported by the NIHR Oxford Biomedical Research Centre (BRC), suggests that pancreatic cancer can be categorised in terms of a person's own immune system. The research also involved colleagues from the universities of Cambridge, Birmingham, Leeds and Maastricht.
The paper, Immuno‐phenotypes of Pancreatic Ductal Adenocarcinoma: Meta‐analysis of transcriptional subtypes, is published in the International Journal of Cancer.
Pancreatic cancer is an aggressive cancer and has limited treatment options. In the early stages of the disease, the tumour often causes few symptoms, which can make it difficult to diagnose. After diagnosis, only 5% of patients survive for five years. Even after an operation in the earliest stages of the disease, only 20% of patients are alive after five years.
Read more (Department of Oncology website)